Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
GH Research Announces Publication of Phase 2b Results for Mebufotenin in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
